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The  recent  introduction  of Droplet  Digital  PCR  (ddPCR)  has  provided  researchers  with  a tool  that  permits
direct  quantiﬁcation  of  nucleic  acids  from  a wide  range  of  samples  with  increased  precision  and  sensitivity
versus RT-qPCR.  The  sample  interdependence  of RT-qPCR  stemming  from  the  measurement  of  Cq and
Cq values  is eliminated  with  ddPCR  which  provides  an  independent  measure  of the absolute  nucleic
acid  concentration  for each  sample  without  standard  curves  thereby  reducing  inter-well  and  inter-plate
variability.  Well-characterized  RNA  puriﬁed  from  H275-wild  type  (WT)  and  H275Y-point  mutated  (MUT)
neuraminidase  of  inﬂuenza  A  (H1N1)  pandemic  2009  virus  was  used  to demonstrate  a ddPCR  optimization
workﬂow  to assure  robust  data  for downstream  analysis.  The  ddPCR  reaction  mix was  also  tested  with
RT-qPCR  and  gave  excellent  reaction  efﬁciency  (between  90%  and  100%)  with  the  optimized  MUT/WTT-qPCR
dPCR
duplexed  assay  thus  enabling  the  direct  comparison  of  the  two  platforms  from the  same  reaction  mix
and  thermal  cycling  protocol.  ddPCR  gave  a marked  improvement  in sensitivity  (>30-fold)  for  mutation
abundance  using  a mixture  of  puriﬁed  MUT  and  WT  RNA  and  increased  precision  (>10 fold,  p <  0.05
for  both  inter-  and  intra-assay  variability)  versus  RT-qPCR  from  patient  samples  to  accurately  identify
residual  mutant  viral  population  during  recovery.
ublis©  2015  The  Authors.  P
. Introduction
Droplet Digital PCR (ddPCR) uses emulsion chemistry to par-
ition 20 L nucleic acid samples into approximately 20,000
il-encapsulated nanodroplets to produce data that surpasses the
recision of RT-qPCR with equivalent or much higher sensitivity
Hindson et al., 2011, 2013). Applications such as rare allele or
utation detection in a complex background or quantiﬁcation of
ucleic acids in samples with high levels of contaminants beneﬁt
rom ddPCR relative to qPCR (Sanmamed et al., 2015; Racˇki et al.,
014). Another major advantage of ddPCR is the elimination of
nterwell, intersample and interplate dependence on data acqui-
ition permitting sample testing throughout a study. For RT-qPCR,
he interdependence of samples and/or standards (based on CT and
CT values (now termed Cq for minimum information for publica-
ion of quantitative real-time PCR experiments (MIQE) compliance
Bustin et al., 2009)) ideally requires running all samples per target
∗ Corresponding author. Tel.: +1 800 268 0213; fax: +1 888 913 9779.
E-mail address: sean taylor@bio-rad.com (S.C. Taylor).
ttp://dx.doi.org/10.1016/j.jviromet.2015.08.014
166-0934/© 2015 The Authors. Published by Elsevier B.V. This is an open access article uhed  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
on the same plate to minimize technical error. In fact, obtaining
reproducible data for the same sample distributed between mul-
tiple labs has been a signiﬁcant challenge with variability up to
three to four logs with RT-qPCR (Zhang et al., 2007; Hayden et al.,
2008). Finally, multiplexing reactions is challenging with RT-qPCR
because of its dependence on reaction efﬁciency as opposed to
ddPCR for which data is acquired at end point and therefore vir-
tually efﬁciency independent to permit the plexing of assays with
much greater ease (Persson et al., 2005; McDermott et al., 2013).
ddPCR has been recently compared to qPCR for detection of viral
nucleic acids with improved precision and elimination of standard
curves (Brunetto et al., 2014; Zhao et al., 2013; Leibovitch et al.,
2014). For many viral strains, resistance to antiviral drug treatment
is conferred through spontaneous point mutations. For immuno-
compromised patients, the accurate detection of these mutations
is critical to effective treatment (Pizzorno et al., 2011; Ghedin
et al., 2012; Corcioli et al., 2014). RT-qPCR has demonstrated a
limit of detection of about 10% for inﬂuenza virus mutation abun-
dance (ratio of point mutant (MUT)/(MUT + wild type (WT)) × 100)
(Escuret et al., 2014). Similar results have been shown with circu-
lating DNA obtained from cancer patients and from solid tumour
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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amples (Angulo et al., 2010; Thomas et al., 2006). Although this
imit of detection is acceptable for categorizing a disease state, it
s not adequate for disease monitoring in cancer or for immuno-
ompromised patients with drug-resistant infection (Oxnard et al.,
014; Watzinger et al., 2004). Here, well-characterized, puriﬁed
NA samples from inﬂuenza A(H1N1)pdm09 virus were used
o demonstrate the key steps to optimize ddPCR experiments.
he optimized assay was then applied to the detection of the
ost frequent inﬂuenza mutation (H275Y) conferring resistance
o Oseltamivir in a mixture of RNA from puriﬁed mutant and wild
ype recombinant viruses and from patient samples over the course
f inﬂuenza infection.
. Materials & methods
.1. RNA samples
.1.1. Puriﬁed RNA samples
RNA was extracted from recombinant inﬂuenza A(H1N1)pdm09
irus (GenBank FN434457 to FN434464) rescued by reverse genet-
cs using bidirectional pLLBA plasmids as previously described
Pizzorno et al., 2011). The H275Y NA mutant was  generated by
erforming site-directed mutagenesis on the plasmid containing
he NA gene.
.1.2. Patient RNA samples
To compare the percent mutation abundance between ddPCR
nd RT-qPCR platforms, nucleic acid extracts of patient samples
ere collected over time. Inﬂuenza A(H1N1)pdm09 virus infec-
ion was diagnosed on January 5, 2011 in a 31 month-old boy
ith medulloblastoma who received consolidation chemother-
py in preparation of an autologous bone marrow transplantation
Ghedin et al., 2012). The child was treated with Oseltamivir (30 mg
ID) from January 6 to 28 and then with Zanamivir (25 mg inhaled
 times daily) until negative RT-qPCR results were obtained on
ebruary 17, 2011. The patient recovered from his infection without
omplication. RNA was extracted from sequential nasopharyngeal
spirates (NPA) using the MagNA Pure total nucleic acid isolation kit
Roche Applies Science) as reported (Ghedin et al., 2012). The RNA
rom the patient sample set to assess intra-assay variability (i.e.,
ame RNA sample pipetted into triplicate wells of the same plate
Table 1)) was extracted on a different day by a different opera-
or than the RNA (from the same patient samples) used to assess
nter-assay variability (i.e., same RNA samples frozen and thawed
t different times and tested in three different plates (Table 2)).
.2. Primers and probes
The primers and probes targeted the H275 (WT) and H275Y
MUT) variants of inﬂuenza A(H1N1)pdm09 virus as previously
escribed (Ghedin et al., 2012) and were purchased from Integrated
NA Technologies (Coralville, Iowa).
.3. RT-qPCR
For patient samples tested for intra-assay variability (see Sec-
ion 2.1.2), the one-step RT-PCR mixture was prepared in a 25 L
eaction volume containing 6.25 L of TaqMan Fast Virus 1-Step
aster Mix  (Applied Biosystems, Foster City, CA), 0.8 L of both the
everse and the forward primers, 1.0 L of each probe and 4.0 L of
NA extract (Pinilla et al., 2012). The ampliﬁcation process was  per-
ormed in a LightCycler 480 real-time thermocycler (Roche Applied
cience, Mannheim, Germany) under the following cycling condi-
ions: 60 ◦C for 30 min  (RT) and 95 ◦C for 5 min  (DNA polymerase
ctivation), followed by 45 cycles of 95 ◦C for 20 s (denaturation)al Methods 224 (2015) 58–66 59
and 62 ◦C for 1 min  (annealing). For all reactions split between RT-
qPCR and ddPCR, the ampliﬁcation process was performed in a
LightCycler 480 real-time thermocycler using the optimized ddPCR
cycling protocol and supermix (see Section 2.7).
2.3.1. Assessment of ddPCR reaction mix for RT-qPCR
Puriﬁed viral RNA (see Section 2.1.1.) from the WT  and MUT
recombinant strains were tested in RT-qPCR using the ddPCR reac-
tion mix to assess primer reaction efﬁciency and linear dynamic
range of RNA samples. Serial, 2-fold dilutions of samples (≈105
diluted to 103 copies per reaction) in 10 mM,  nuclease-free Tris
buffer (pH 7.5) were used as template with the duplexed WT/MUT
primer/probes using the ddPCR reaction supermix and associated
cycling protocol (see Section 2.4) for detection of WT/MUT virus in
both RT-qPCR and ddPCR (Supplemental Fig. S1).
2.4. ddPCR
Twenty microliters of each reaction mix  was  converted to
droplets with the QX200 droplet generator (Bio-Rad). Droplet-
partitioned samples were then transferred to a 96-well plate, sealed
and cycled in a C1000 deep well Thermocycler (Bio-Rad) under
the following cycling protocol: 60 ◦C for 30 min (RT) and 95 ◦C for
5 min  (DNA polymerase activation), followed by 40 cycles of 95 ◦C
for 30 s (denaturation) and 55 ◦C for 1 min  (annealing) followed by
post-cycling steps of 98 ◦C for 10 min  (enzyme inactivation) and
an inﬁnite 10 degree hold. The cycled plate was  then transferred
and read in the FAM and HEX channels using the QX200 reader
(Bio-Rad) either the same or the following day post-cycling.
2.5. Primer/probe thermal gradient optimization
Serial 10-fold dilutions (104 to 106 copies per reaction) in
10 mM,  nuclease-free Tris buffer (pH 7.5) of puriﬁed viral RNA from
the WT,  MUT  and mixtures of WT/MUT recombinant strains were
used as template to assess the optimal annealing temperature of
the individual and duplexed primer/probes. The standard ddPCR
cycling program was  modiﬁed by replacing the annealing tempera-
ture step with a thermal gradient between 52 ◦C and 64 ◦C for 1 min
extension time (Fig. 1).
2.6. Standard curve and controls for ddPCR
A 1/2 dilution of the MUT  RNA in a constant WT background
(Fig. 2B) and the inverse experiment with diluted WT in constant
MUT  background (data not shown) was produced. Duplicate con-
trol samples containing either MUT  or WT RNA were also tested
with the duplexed MUT/WT primer/probes to determine the level
of crosstalk and the lower limit of reliable quantiﬁcation for the
duplex assay (Fig. 2A2). A traditional no template control was  also
sampled (Fig. 2A3).
2.7. Split reactions between RT-qPCR and ddPCR
For puriﬁed RNA samples and patient samples tested for intra-
assay variability, a total of 50 L reaction mix was prepared using
25 L of ddPCR supermix (One-Step RT-ddPCR Kit for Probes for
RNA (Bio-Rad)), primers and probes to a ﬁnal concentration of
800 nM and 200 nM,  respectively, and inﬂuenza virus RNA at a con-
centration of 0.33 pg or 1 × 105 copies per well. Twenty L aliquots
of these reaction mixes were used to quantify samples by RT-qPCR
and ddPCR under optimized ddPCR cycling conditions (see Section
2.4). For patient samples tested for inter-assay variability, a 44 L
reaction mix  was prepared from 22 L of ddPCR supermix, primers
and probes and RNA as above. Twenty L aliquots of these reaction
60 S.C. Taylor et al. / Journal of Virological Methods 224 (2015) 58–66
Table  1
Assessing intra-assay variability between ddPCR and RT-qPCR. Triplicate experiments for both ddPCR and RT-qPCR were performed as typical technical replicates from the
same  RNA samples extracted from a set of patient samples and pipetted on the same plate for each respective platform. Identical RNA samples were tested with RT-qPCR
and  ddPCR using different PCR reagents and cycling conditions (see Sections 2.3 and 2.4). H: wild type; Y: H275Y point mutant; %: mean mutation abundance for H (copies of
H/(copies of H + Y) × 100) for triplicate replicates; %CV: coefﬁcient of variation between replicates ((standard deviation/mean) × 100); p-value: statistical signiﬁcance of the
mean  % mutation abundance between successive sampling dates. Arrows indicate the successive pairs of sampling dates compared for statistical analysis.
Fig. 1. Combined thermal gradient and sample concentration optimization for primer/probe annealing temperature in single and duplex assays. Schematic for the ddPCR
thermal gradient optimization experiment depicting recommended dilutions of cDNA or gDNA and primer annealing temperature range (A). The optimal annealing temper-
ature  range and orthogonal 2D amplitude plot are shown for the dilution corresponding to 25 Cq (105 copies) from the RT-qPCR data for the MUT, WT and mixed MUT/WT
RNA  samples which was approximately in the middle of the linear dynamic range for ddPCR (about 250 copies per L) (B). Droplets color code: Gray: negative; Green: Hex
probe  for MUT  target; Blue: Fam probe for WT  target; Orange: double positive droplets containing both MUT  and WT targets.
S.C. Taylor et al. / Journal of Virological Methods 224 (2015) 58–66 61
Fig. 2. Validation of the quantitative linear dynamic range for ddPCR. 2D Amplitude plots of the raw data are shown for ddPCR for the third dilution of the MUT/WT  dilution
series  (A1), the negative control sample with WT virus only (A2) and the no template control (water) (A3). A 1/2 dilution series of MUT  in a constant WT RNA mixtures were
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rror  bars indicate the Poisson 95% conﬁdence intervals for each copy number dete
nd  MUT  CPM values.
ixes were used to quantify samples by RT-qPCR and ddPCR under
ptimized ddPCR cycling conditions.
.8. Percent mutation abundance, statistical analysis and
alculation of the coefﬁcient of variation
For both RT-qPCR and ddPCR, the percent mutation abun-
ance was calculated from the mean copy per L (CPM) of
he triplicate replicate patient samples (WT/(MUT + WT)  × 100) or
MUT/(MUT + WT)  × 100) and summarized with the coefﬁcient of
ariation (standard deviation/mean × 100). All populations were
ormally distributed using the Shapiro–Wilk test. A Student t
ndividual paired comparisons test was chosen to determine the
tatistical signiﬁcance between mean percent mutation abundance
f each successive date for patient sampling (De Winter, 2013). A
able 2
ssessing inter-assay variability between ddPCR and RT-qPCR for independent experimen
ent  replicates from fresh extracts of RNA (and different from those tested in Table 1 from
imes  and assayed on three different plates for both platforms. In order to more directly co
or  each RNA sample and split between ddPCR and RT-qPCR for each experiment (see S
or  H (copies of H/(copies of H + Y) × 100) for triplicate replicates; %CV: coefﬁcient of va
igniﬁcance of the mean % mutation abundance between successive sampling dates. Arrow (B). Each point displays the copies per L (CPM) for MUT  and WT in each sample.
tion. Mutation abundance is calculated by dividing the MUT  CPM by the sum of WT
Kendall tau correlation test was  applied to the RT-qPCR and ddPCR
data to measure the association between mutation abundance data
generated for the patient samples tested within each platform and
between the different RNA extracts used for intra- and inter-assay
variability analysis (Fig. 4).
3. Results
3.1. Using RT-qPCR to assess primer efﬁciency in the ddPCR
reaction mix and to approximate the dilution factor for ddPCR
analysis of RNA and cDNAddPCR as applied to the QX200 has a quantitative linear dynamic
range between 1 and 5000 copies per microliter (ie: 20 to 100,000
copies) and a lower limit of sensitivity of about 4 copies in a single
ts. Triplicate experiments for both ddPCR and RT-qPCR were performed as indepen-
 the original patient samples). The RNA was frozen and thawed at three different
mpare the results between ddPCR and RTqPCR, a single reaction mix  was produced
ection 2.7). H: wild type; Y: H275Y point mutant; %: mean mutation abundance
riation between replicates ((standard deviation/mean) × 100); p-value: statistical
s indicate the successive pairs of sampling dates compared for statistical analysis.
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0 L reaction. This corresponds to a range of about 22 to 35 Cq
ith RT-qPCR but should be tested for speciﬁc experiments using
 pooled sample from all the experimental conditions. Assessing a
erially diluted sample (pooled RNA, cDNA, gDNA) or possibly DNA
rom a cloned plasmid or PCR product (as a positive control) for
ach primer/probe set using standard RT-qPCR will reveal the reac-
ion efﬁciency, linear dynamic range and the approximate dilution
actor required to avoid saturation of the ddPCR reaction.
In order to directly compare the RT-qPCR and ddPCR platforms,
he ideal experiments would be designed using the same reac-
ion mix  and cycling protocol such that the platform (RT-qPCR or
dPCR) represents the only difference between the results. Given
hat standard RT-qPCR supermixes are not compatible with ddPCR
ecause they leach out of the oil-encased droplets, the ddPCR super-
ix  was assessed for compatibility with RT-qPCR. Both the MUT
nd WT  primer/probes gave optimal reaction efﬁciencies between
0 and 110% (as deﬁned by the MIQE guidelines) in RT-qPCR using
he ddPCR supermix and cycling conditions (Supplemental Fig. S1)
upporting its applicability as a uniﬁed reagent to compare both
latforms. The dilution corresponding to 24 Cq (i.e., 106 copies for
his experiment) was used as the starting sample with two  addi-
ional 1/10 dilutions (i.e., 105 and 104 copies) for primer/probe
nnealing temperature optimization with ddPCR.
.2. Primer/probe annealing temperature, RNA concentration and
rthogonality of droplet separation in the duplex assay
In a typical optimization experiment, a pooled RNA or cDNA
ample (diluted at least 1/10) from all the study sample sets should
nitially be tested in RT-qPCR with all primers pairs and then diluted
o approximately 22 Cq for each target for the ddPCR thermal gra-
ient optimization experiment (Fig. 1A). However, if the Cq value
rom the 1/10 pooled sample is beyond 22 Cq, then the undiluted,
ooled sample should be used as the starting sample for ddPCR
ptimization. For genomic DNA, 10 to 50 ng of pooled DNA from
he study sets should be used for ddPCR optimization (Fig. 1A).
WT and MUT  RNA from inﬂuenza A(H1N1)pdm09 virus were
erially diluted 1/10 and tested with the duplex WT/MUT primer
robe set in RT-qPCR for thermal gradient optimization. The sample
ilution corresponding to 25 Cq (105 copies) was approximately
n the middle of the linear dynamic range for ddPCR (about 250
opies per L) and the optimal range of annealing temperatures
iving the largest difference in ﬂuorescence between negative and
ositive droplets was between 52 ◦C and 55.4 ◦C for both MUT  and
T primers (Fig. 1B). An optimized annealing temperature of 55 ◦C
as chosen for the subsequent experiments and the duplexed assay
ave good, orthogonal separation between the MUT, WT,  negative
nd MUT/WT double positive droplet species in the 2D amplitude
lot (Fig. 1B).
.3. Determination of the linear, quantitative dynamic range for
dPCR and lower limit of quantiﬁcation
A standard curve with the appropriate negative controls remains
he most reliable method to assure that samples are diluted to
n appropriate concentration to achieve the highest quality data
or most analytical methods including RT-qPCR and even quanti-
ative western blotting (Taylor and Mrkusich, 2014; Taylor et al.,
013). The same holds true for ddPCR where a 1/2 dilution of the
UT RNA in a constant WT  background (Fig. 2B) and the inversexperiment with diluted WT  in constant MUT  background (data
ot shown) gave the predicted two fold reduction in RNA concen-
ration over the entire range tested. Also, the 2D-amplitude plot
rom each dilution gave the expected orthogonality for each dropletal Methods 224 (2015) 58–66
species (Fig. 2A1). Negative controls were used to assure samples
were diluted appropriately (Figs. 2A2 and A3).
3.4. Divergent data between ddPCR and qPCR for quantiﬁcation
of puriﬁed RNA samples
qPCR and ddPCR gave highly divergent data with respect to pre-
cision and sensitivity. For the 1/2 diluted MUT  RNA samples, there
was a single Cq difference between the ﬁrst two samples for RT-
qPCR and the remaining dilutions converged at the same Cq value
whereas for ddPCR the data closely correlated to the expected 2-
fold dilution factor over all seven dilutions. This corresponds to a
mutation abundance limit of detection (LOD) of about 50% for RT-
qPCR and 1.41% for ddPCR and thus an increase in sensitivity of
about 30 fold for this particular duplex inﬂuenza assay (Fig. 3).
3.5. Application of ddPCR to quantify viral populations from
patient samples with inﬂuenza A(H1N1)pdm09 H275Y mutant
infection
The relative percent abundance of viral load present in sequen-
tial NPA samples of an immunocompromised child for both the
WT and MUT  virus subpopulations was quantiﬁed using RT-qPCR
and ddPCR to assess reproducibility and precision (Tables 1 and 2).
When one set of RNA samples was  tested for intra-assay variabil-
ity under optimized conditions using the respective RT-qPCR and
ddPCR reagents and cycling conditions, the %CV was greater than
10 fold higher (from 45 to 109.7%) for RT-qPCR compared to ddPCR
(0.9 to 11.4%) and gave insigniﬁcant results between all the sam-
ples (p-value > 0.05) for RT-qPCR (Table 1). Similarly, when a second
set of RNA extracts from the same patient samples were tested for
inter-assay variability using the ddPCR reaction mix and cycling
protocol, the %CV of the viral load remained about 10 fold higher
with mostly insigniﬁcant results for RT-qPCR (Table 2). Alterna-
tively, ddPCR gave precise and signiﬁcant results (p-value < 0.05)
with low variability (Tables 1 and 2).
A Kendall tau correlation test was applied to the RT-qPCR
and ddPCR data to measure the association between the different
RNA extracts used for intra- and inter-assay variability analysis.
There was no signiﬁcant correlation (p-value = 0.0909; tau = 0.600)
between the data sets for RT-qPCR (Fig. 4A) and a strong correlation
(p-value = 0.0048; tau = 1.000) between the ddPCR data (Fig. 4B).
4. Discussion
ddPCR permits a multidimensional approach to assay optimiza-
tion through the examination of both droplet amplitude and scatter
coupled with absolute quantiﬁcation of DNA and RNA concentra-
tion. Unlike RT-qPCR where the data are measured from a single
ampliﬁcation curve and a Cq value that is highly dependent on reac-
tion efﬁciency, primer dimers and sample contaminants, ddPCR is
measured at reaction end point which virtually eliminates these
potential pitfalls. Despite these beneﬁts, experimental optimiza-
tion remains a requirement for ddPCR to ensure the ﬁnal results
produce solid, interpretable data (Fig. 1A). The hallmarks of an opti-
mized, duplex assay for ddPCR include: an orthogonal 2D amplitude
plot for the duplexed assay (Fig. 1B); a similar measured concen-
tration (within 10%) of target amplicons between the single and
duplexed primer/probe assays and between technical replicates
taking into account any concentration differences between the
samples for each test; optimized assay separation between positive
and negative droplets, or maximal ﬂuorescence amplitude indica-
tive of an efﬁcient PCR reaction and typically veriﬁed by thermal
gradient (Fig. 1B); a standard curve from a serially diluted sam-
ple with either single or duplexed primer/probes and appropriate
S.C. Taylor et al. / Journal of Virological Methods 224 (2015) 58–66 63
Fig. 3. RT-qPCR and ddPCR from a mock mutation abundance experiment with RNA. A 1/2 dilution series of MUT  in a constant WT RNA mixture was  quantiﬁed from the
same  mixture of One-Step RT-ddPCR Kit for Probes, duplex MUT/WT primer probes and RNA that was split between ddPCR and RT-qPCR reactions to directly compare the
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aw  data are shown for ddPCR for the third dilution of each MUT/WT dilution seri
utation abundance is calculated by dividing the MUT  CPM by the sum of WT and 
egative controls to assess the dynamic range and precision of each
dPCR assay (Fig. 2).
Sample partitioning not only improves precision of ddPCR
ersus RT-qPCR but, in the case of mutation abundance assays,
ensitivity is also increased signiﬁcantly as shown here for the
ock mutation abundance experiment where qPCR could not
esolve dilutions of MUT  RNA in the WT  background (Fig. 3). When
pplied to immunocompromised, inﬂuenza patients infected with
oth the MUT  (Y) and WT (H) viral strains, the detection and
ccurate quantiﬁcation of the relative abundance of each strain
n a duplexed MUT/WT primer/probe assay is critical for appro-
riate selection of drug treatment regimen. Here, the RT-qPCR
esults did give a decrease in the WT  strain with a concomitant
ncrease in the MUT  strain after Oseltamivir treatment betweenﬁdence intervals for each copy number determination. 2D Amplitude plots of the
et). Each point displays the copies per L (CPM) for MUT  and WT in each sample.
PM values.
1/10/2011 and 1/17/2011. However, the high intra-assay variability
(%CV), large and unpredictable shifts in mutation abundance post-
treatment and statistically insigniﬁcant differences between all of
the sampling dates (p-value > 0.05) made it challenging to interpret
the RT-qPCR data (Table 1). Although the inter-assay variability
between the RT-qPCR data was generally lower and gave a sta-
tistically signiﬁcant shift in mutation abundance after Oseltamivir
treatment between 1/10/2011 and 1/17/2011 (Table 2), the rest of
the sampling dates were not statistically signiﬁcant. For both sets
of experiments, the ddPCR results exhibited a precise shift in popu-
lation of viral strains versus RT-qPCR with a large shift between the
viral populations after Oseltamivir treatment followed by a con-
tinued decrease in WT  virus with a concomitant increase in the
MUT  form (Tables 1 and 2). The increased precision and statistical
64 S.C. Taylor et al. / Journal of Virological Methods 224 (2015) 58–66
Fig. 4. Assay correlation of RT-qPCR and ddPCR from different RNA extracts (produced from different operators on different dates) of the same patient samples. The mutation
abundance of the WT virus population was compared between two  independent assays from the same set of inﬂuenza infected patient samples for RT-qPCR (A) and ddPCR
(B)  with data extracted from Tables 1 and 2 for intra-assay and inter-assay replicates respectively. Intra-assay Reps: experiment using RNA extracts from three technical
replicates pipetted simultaneously from the same, thawed RNA sample at each time point assayed on the same plate at the same time for all samples. Inter-assay Reps:
experiment from different RNA extracts (different operator extracted the RNA on a different date) of the same patient samples frozen and thawed at three different times
and  pipetted on three, separate plates for each replicate. For Inter-assay Reps, the reagents and thermal cycling protocols for RT-qPCR and ddPCR were shared between each
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ime  point (see Tables 1 and 2). There was no signiﬁcant correlation (p-value = 0.090
orrelation (p-value = 0.0048; tau = 1.000) between the ddPCR data (B).
igniﬁcance between the successive sampling dates from ddPCR
nabled the assessment of treatment with conﬁdence.
ddPCR is an excellent tool for studies requiring sample
rocessing over longer time frames such as weeks, months or years.
lso, projects that evolve to include new treatment groups or time
oints which would be challenging for RT-qPCR where interplate
ariability can be a signiﬁcant source of error. Examples of such
tudies include the collection of rare tumour, tissue or blood sam-
les that may  take several months or years to build the study
ohort. Other examples could be dynamic patient studies similar
o those used here where the results for a given sampling date
re required to make decisions for treatment on subsequent dates.
ven a simple gene expression experiment that requires com-
arison of previously collected data with results generated from
ew experimental conditions would beneﬁt greatly from ddPCRee Sections 2.3 and 2.4). * p-Value < 0.05 between each successive patient sampling
 = 0.600) between the inter- and intra-assay data sets for RT-qPCR (A) and a strong
because of the elimination of sample interdependence that con-
tributes to the variability in RT-qPCR. This is exempliﬁed with
the inﬂuenza patient samples used in this study, where the data
acquired from two, independently processed RNA extracts from
the same series of patient samples were highly correlated for
ddPCR and uncorrelated for RT-qPCR (Fig. 4). Many studies have
shown divergent results between laboratories when processing the
same samples with RT-qPCR (Zhang et al., 2007; Hayden et al.,
2008). The variability in RT-qPCR data is often attributed to the
methods used to determine the concentration of standards and
the lack of rigor in the production of standard curves for primer
validation and absolute quantiﬁcation (Svec et al., 2015). Conse-
quently, labs are now suggesting the use of ddPCR to validate the
concentration of the standards used for RT-qPCR (Hayden et al.,
2015).
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Although there are now hundreds of publications that under-
ine the beneﬁts of ddPCR, there have been reports concluding that
T-qPCR surpasses ddPCR in sensitivity and precision for clinical
amples (Hayden et al., 2013). Although the Hayden study used
ontrolled samples, the reaction conditions between ddPCR and
T-qPCR were much different in terms of cycling protocols, reaction
ixes and total volumes which may  account for this discrepancy
s noted by the authors. This brings to question the level at which
hese assays were optimized which is unfortunately not possible to
ssess as is the case for much of the data published with RT-qPCR
Bustin et al., 2013; Dijkstra et al., 2013). Optimizing ddPCR assays
ill assure excellent data quality, precision and reproducibility for
his highly sensitive technique as shown for the detection of drug-
esistant inﬂuenza populations in the present study.
. Conclusions
A rigorous approach to ddPCR assay optimization was applied
o the quantiﬁcation of standardized H275 (WT) and H275Y (MUT)
trains of inﬂuenza A(H1N1)pdm09 virus to directly compare RT-
PCR and ddPCR where the latter gave a 30-fold increase in
ensitivity (Fig. 3). The optimized assay was then applied to virus
NA puriﬁed from human nasal swab samples where ddPCR gave
recise, interpretable and statistically signiﬁcant results relative to
T-qPCR (Tables 1 and 2). Furthermore, the ddPCR data produced
 statistically signiﬁcant correlation between two  sets of inde-
endently extracted RNA from the same patient samples (Fig. 4).
ased on these results, ddPCR offers a viable alternative to RT-qPCR
o obtain precise quantiﬁcation of nucleic acids extracted from a
ide range of samples for reliable interpretation without standard
urves or sample interdependence.
ppendix A. Supplementary data
Supplementary data associated with this article can be found,
n the online version, at http://dx.doi.org/10.1016/j.jviromet.2015.
8.014.
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